ClinicalTrials.gg
RecruitingNCT00582621Updated Jan 23, 2026

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

An observational study in Lymphoma, Leukemia and Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 6 sites in United States. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Lymphoma by Memorial Sloan Kettering Cancer Center — 10 open to participants now, 18 under way, none of them phase 3. Lymphoma · Memorial Sloan Kettering Cancer Center.

Planned enrollment
Largest of 10
500 · median 43
Started
2000
with 7 others
Observational
10 of 99
3 open now
Primary completion
2026-12
later than 1 of 17 live
Registered
53rd of 99
by date

Among the 99 studies in Lymphoma by Memorial Sloan Kettering Cancer Center, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 8 that started in 2000, is one of 10 observational ones, reaches primary completion later than 1 of the 17 other live ones, and was the 53rd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

10 of the 99 studies in Lymphoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Lymphoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease and/or, non-Hodgkin's lymphoma or a second cancer after Hodgkin's disease.

03

Conditions studied

  • Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Colon Cancer
  • Renal Cancer

Keywords

  • Genetic Studies
  • 00-069
  • blood
  • saliva
  • buccal cell
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Clinical Genetics Service at MSKCC or to the MSKCC outpatient clinics of the Lymphoma, Multiple Myeloma or Leukemia Services in the Department of Medicine.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a personal and/or family history of lymphoma or lymphoproliferative disease B-cell , or multiple myeloma referred for study participation, or MSK patients referred from to the MSKCC outpatient clinics of the Lymphoma, Multiple Myeloma, or Leukemia Services in the Department of Medicine in consultation for treatment who are found on routine history or through a Family History Questionnaire (FHQ) (Appendix A). Individuals who have relatives or members of successive generations of the family affected with Hodgkin's disease, non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma other lymphoproliferative disease prostate or pancreatic cancers, or other conditions suggesting hereditary cancer at the discretion of the MSKCC Principal Investigator. Patients with lymphoma, associated with colon and renal cancer will be eligible for DNA storage through this protocol. Family members or probands with Hodgkin's disease who are women who received therapeutic irradiation for Hodgkin's disease" or who developed secondary cancers after Hodgkin's disease are also eligible for participation.
  • The criteria for eligibility are broad because the ascertainment by the computerized FHQ does not allow for resolution of different types of lymphoma or different types of leukemia. Patient recall of this information is also imprecise. More accurate family history information will be obtained upon contact of family members and diagnoses will be verified by obtaining pathologic documentation. The spectrum of familial lymphoproliferative syndromes (LPS) may include all types of lymphoma as well as chronic lymphocytic leukemia. This is an additional reason to have a broad eligibility. Subset analysis will be performed on specific types of lymphoid neoplasms. DNA of patients with a family history of lymphoma who have consented to protocol 93-102 ("Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers") will also be eligible for inclusion in this study.
  • Family members of probands including patients, sisters, brothers, halfbrothers and sisters, sons, daughters, grandparents, as well as aunts and uncles are also eligible. An effort will be made to ascertain all living affected and unaffected living relatives in the affected lineage. An emphasis will be on affected sibling pairs and both parents, if alive.
  • As this study involves research that presents no greater than minimal risk to children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible for participation. The assent of any minor should be obtained before the patient is enrolled into this study, as well as the consent of the legal guardian.

Exclusion criteria

Exclusion Criteria:

  • N/A
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
500 participants (estimated)
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. To establish a collection of DNA and frozen lymphocytes for the purpose of facilitating genetic laboratory investigations of familial lymphoid neoplasms.

    Time frame: 2 years

Secondary outcomes

  1. To perform linkage and candidate gene studies on informative families for the purpose of identifying novel lymphoproliferative syndrome (LPS) predisposition genes.

    Time frame: 2 years

07

Study locations

6 of 6 sites recruiting
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Kenneth Offit, MD, MPH · Contact646-888-4050
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
    Recruiting
    • Kenneth Offit, MD, MPH · Contact646-888-4050
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
    Recruiting
    • Kenneth Offit, MD, MPH · Contact646-888-4050
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
    Recruiting
    • Kenneth Offit, MD, MPH · Contact646-888-4050
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Kenneth Offit, MD, MPH · Contact646-888-4050
  • Memorial Sloan Kettering Rockville
    Rockville Centre, New York 11570, United States
    Recruiting
    • Kenneth Offit, MD, MPH · Contact646-888-4050
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2000, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Dec 28, 2007
Start
Jul 2000
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00582621
Responsible party
Sponsor
First posted
Dec 28, 2007
Start date
Jul 2000
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 23, 2026

Study contacts

Kenneth Offit, MD
Contact
646-888-4050
Gilles Salles, MD, PhD
Contact
SallesG@mskcc.org
646-608-2642
Kenneth Offit, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion